Patrick Donnelly
Stock Analyst at Citigroup
(3.54)
# 846
Out of 5,141 analysts
369
Total ratings
49.75%
Success rate
5.13%
Average return
Main Sectors:
Stocks Rated by Patrick Donnelly
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| GH Guardant Health | Maintains: Buy | $135 → $150 | $103.10 | +45.49% | 12 | Feb 20, 2026 | |
| BRKR Bruker | Maintains: Neutral | $53 → $40 | $38.28 | +4.49% | 19 | Feb 13, 2026 | |
| QDEL QuidelOrtho | Maintains: Neutral | $23 → $30 | $22.48 | +33.45% | 7 | Feb 12, 2026 | |
| AVTR Avantor | Maintains: Neutral | $13 → $11 | $9.03 | +21.82% | 9 | Feb 12, 2026 | |
| DGX Quest Diagnostics | Maintains: Neutral | $190 → $215 | $202.41 | +6.22% | 12 | Feb 10, 2026 | |
| QGEN Qiagen | Maintains: Neutral | $55 → $55 | $48.57 | +13.24% | 15 | Feb 6, 2026 | |
| IQV IQVIA Holdings | Maintains: Neutral | $230 → $200 | $165.62 | +20.76% | 14 | Feb 6, 2026 | |
| TECH Bio-Techne | Maintains: Buy | $70 → $80 | $57.52 | +39.08% | 13 | Feb 5, 2026 | |
| TMO Thermo Fisher Scientific | Maintains: Buy | $660 → $685 | $510.93 | +34.07% | 22 | Jan 30, 2026 | |
| CRL Charles River Laboratories International | Maintains: Buy | $200 → $265 | $168.92 | +56.88% | 22 | Jan 16, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $48 | $49.80 | -3.61% | 1 | Jan 12, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $300 | $212.12 | +41.43% | 1 | Jan 7, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $18 | $18.88 | -4.66% | 13 | Dec 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $12 → $21 | $11.00 | +90.91% | 5 | Dec 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $165 → $185 | $122.90 | +50.53% | 27 | Nov 25, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $1,600 → $1,700 | $1,377.55 | +23.41% | 15 | Nov 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $350 → $375 | $271.30 | +38.22% | 17 | Oct 30, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $350 → $375 | $261.83 | +43.22% | 17 | Oct 30, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $225 → $200 | $99.70 | +100.60% | 10 | Aug 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $34 → $42 | $19.53 | +115.05% | 2 | Aug 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $60 → $80 | $75.43 | +6.06% | 15 | Jul 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Sell | $85 → $80 | $117.67 | -32.01% | 17 | Jul 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $285 → $265 | $209.50 | +26.49% | 12 | Jan 30, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $18 → $20 | $17.49 | +14.35% | 3 | Nov 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $80 → $75 | $103.43 | -27.49% | 13 | Nov 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $30 → $28 | $16.05 | +74.45% | 4 | Aug 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $135 → $145 | $100.33 | +44.52% | 1 | Jul 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $265 → $300 | $333.33 | -10.00% | 24 | Dec 11, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $7 → $9 | $2.75 | +227.27% | 6 | Dec 11, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $3.75 → $2.75 | $2.51 | +9.56% | 4 | Aug 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $250 → $260 | $282.67 | -8.02% | 11 | Feb 17, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $8 → $6 | $8.28 | -27.54% | 4 | Nov 3, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | $28 → $32 | $4.29 | +645.92% | 2 | Nov 30, 2018 |
Guardant Health
Feb 20, 2026
Maintains: Buy
Price Target: $135 → $150
Current: $103.10
Upside: +45.49%
Bruker
Feb 13, 2026
Maintains: Neutral
Price Target: $53 → $40
Current: $38.28
Upside: +4.49%
QuidelOrtho
Feb 12, 2026
Maintains: Neutral
Price Target: $23 → $30
Current: $22.48
Upside: +33.45%
Avantor
Feb 12, 2026
Maintains: Neutral
Price Target: $13 → $11
Current: $9.03
Upside: +21.82%
Quest Diagnostics
Feb 10, 2026
Maintains: Neutral
Price Target: $190 → $215
Current: $202.41
Upside: +6.22%
Qiagen
Feb 6, 2026
Maintains: Neutral
Price Target: $55 → $55
Current: $48.57
Upside: +13.24%
IQVIA Holdings
Feb 6, 2026
Maintains: Neutral
Price Target: $230 → $200
Current: $165.62
Upside: +20.76%
Bio-Techne
Feb 5, 2026
Maintains: Buy
Price Target: $70 → $80
Current: $57.52
Upside: +39.08%
Thermo Fisher Scientific
Jan 30, 2026
Maintains: Buy
Price Target: $660 → $685
Current: $510.93
Upside: +34.07%
Charles River Laboratories International
Jan 16, 2026
Maintains: Buy
Price Target: $200 → $265
Current: $168.92
Upside: +56.88%
Jan 12, 2026
Initiates: Buy
Price Target: $48
Current: $49.80
Upside: -3.61%
Jan 7, 2026
Initiates: Buy
Price Target: $300
Current: $212.12
Upside: +41.43%
Dec 11, 2025
Downgrades: Neutral
Price Target: $18
Current: $18.88
Upside: -4.66%
Dec 11, 2025
Upgrades: Buy
Price Target: $12 → $21
Current: $11.00
Upside: +90.91%
Nov 25, 2025
Maintains: Buy
Price Target: $165 → $185
Current: $122.90
Upside: +50.53%
Nov 10, 2025
Maintains: Buy
Price Target: $1,600 → $1,700
Current: $1,377.55
Upside: +23.41%
Oct 30, 2025
Maintains: Buy
Price Target: $350 → $375
Current: $271.30
Upside: +38.22%
Oct 30, 2025
Maintains: Buy
Price Target: $350 → $375
Current: $261.83
Upside: +43.22%
Aug 21, 2025
Downgrades: Neutral
Price Target: $225 → $200
Current: $99.70
Upside: +100.60%
Aug 13, 2025
Maintains: Buy
Price Target: $34 → $42
Current: $19.53
Upside: +115.05%
Jul 9, 2025
Upgrades: Buy
Price Target: $60 → $80
Current: $75.43
Upside: +6.06%
Jul 9, 2025
Downgrades: Sell
Price Target: $85 → $80
Current: $117.67
Upside: -32.01%
Jan 30, 2025
Maintains: Buy
Price Target: $285 → $265
Current: $209.50
Upside: +26.49%
Nov 6, 2024
Maintains: Buy
Price Target: $18 → $20
Current: $17.49
Upside: +14.35%
Nov 6, 2024
Maintains: Buy
Price Target: $80 → $75
Current: $103.43
Upside: -27.49%
Aug 7, 2024
Maintains: Buy
Price Target: $30 → $28
Current: $16.05
Upside: +74.45%
Jul 30, 2024
Maintains: Buy
Price Target: $135 → $145
Current: $100.33
Upside: +44.52%
Dec 11, 2023
Maintains: Neutral
Price Target: $265 → $300
Current: $333.33
Upside: -10.00%
Dec 11, 2023
Maintains: Buy
Price Target: $7 → $9
Current: $2.75
Upside: +227.27%
Aug 10, 2023
Maintains: Neutral
Price Target: $3.75 → $2.75
Current: $2.51
Upside: +9.56%
Feb 17, 2023
Maintains: Neutral
Price Target: $250 → $260
Current: $282.67
Upside: -8.02%
Nov 3, 2022
Maintains: Buy
Price Target: $8 → $6
Current: $8.28
Upside: -27.54%
Nov 30, 2018
Upgrades: Neutral
Price Target: $28 → $32
Current: $4.29
Upside: +645.92%